Cocrystal Pharma, Inc. (NASDAQ:COCP) Short Interest Update

Cocrystal Pharma, Inc. (NASDAQ:COCP) was the recipient of a significant growth in short interest in the month of January. As of January 30th, there was short interest totaling 202,066 shares, a growth of 26.0% from the January 15th total of 160,347 shares. Approximately 2.0% of the shares of the company are short sold. Based on an average trading volume of 66,811 shares, the days-to-cover ratio is presently 3.0 days. Based on an average trading volume of 66,811 shares, the days-to-cover ratio is presently 3.0 days. Approximately 2.0% of the shares of the company are short sold.

Cocrystal Pharma Stock Up 3.8%

Shares of Cocrystal Pharma stock opened at $0.96 on Monday. The firm has a market cap of $13.30 million, a PE ratio of -1.03 and a beta of 1.20. Cocrystal Pharma has a twelve month low of $0.86 and a twelve month high of $2.67. The business has a 50-day moving average price of $1.02 and a 200 day moving average price of $1.19.

Cocrystal Pharma (NASDAQ:COCP) last issued its quarterly earnings data on Friday, November 14th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.03. On average, sell-side analysts expect that Cocrystal Pharma will post -1.85 EPS for the current year.

Insider Buying and Selling at Cocrystal Pharma

In other Cocrystal Pharma news, Director Phillip Md Et Al Frost purchased 50,000 shares of the stock in a transaction on Friday, February 6th. The shares were bought at an average cost of $0.95 per share, with a total value of $47,500.00. Following the completion of the acquisition, the director owned 1,888,551 shares in the company, valued at $1,794,123.45. This trade represents a 2.72% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders have acquired a total of 209,000 shares of company stock valued at $200,210 in the last quarter. 28.14% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Cocrystal Pharma

A hedge fund recently bought a new stake in Cocrystal Pharma stock. T3 Companies LLC purchased a new position in Cocrystal Pharma, Inc. (NASDAQ:COCP) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 52,300 shares of the company’s stock, valued at approximately $51,000. T3 Companies LLC owned about 0.38% of Cocrystal Pharma at the end of the most recent reporting period. 6.72% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Cocrystal Pharma in a research note on Monday, December 22nd. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $6.00.

About Cocrystal Pharma

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.